Dasatinib in chronic myeloid leukemia: a review

Deregulated BCR-ABL tyrosine kinase (TK) activity is the molecular marker for chronic myeloid leukemia (CML), which provides an identifiable target for developing therapeutic agents. Imatinib mesylate, a BCR-ABL TK inhibitor, is the frontline therapy for CML. Despite the stunning efficacy of this ag...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Aguilera, Dolly G, Tsimberidou, Apostolia M
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2009
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2697539/
https://ncbi.nlm.nih.gov/pubmed/19536317
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki